Does Cosentyx Interact with Vaccines?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses the immune system and can reduce vaccine effectiveness, particularly for live vaccines. The prescribing information warns against live vaccines during treatment due to infection risk.[1]
What Vaccines Should You Avoid on Cosentyx?
Avoid live vaccines like MMR (measles, mumps, rubella), varicella (chickenpox), oral polio, yellow fever, and some rotavirus or typhoid vaccines. These can replicate in the body and cause disease in immunocompromised patients. Inactivated or recombinant vaccines—such as flu (injected), COVID-19, shingles (Shingrix), pneumococcal, and hepatitis—are generally safe but may produce weaker immune responses.[1][2]
How Does Cosentyx Affect Vaccine Response?
Clinical studies show diminished antibody responses to vaccines like tetanus toxoid and pneumococcal polysaccharide while on Cosentyx. For example, seroprotection rates dropped for tetanus (from 100% pre-treatment to 56% post-treatment). Responses recover after stopping the drug, typically 12-24 weeks later.[1] Real-world data confirms reduced efficacy for COVID-19 vaccines in IL-17 inhibitor users.[3]
Timing Vaccines with Cosentyx Treatment
Administer non-live vaccines before starting Cosentyx if possible, ideally 2-4 weeks prior. If already on treatment, consider pausing Cosentyx (after consulting a doctor) or vaccinating during a treatment break. Post-vaccination antibody testing may be needed for high-risk patients.[1][2]
What Do Guidelines Say for Patients?
The American College of Rheumatology recommends non-live vaccines for all biologic users, including Cosentyx, and live vaccines only if benefits outweigh risks (e.g., in low-immunosuppression states). Update routine vaccines like Tdap, flu, and COVID before or during therapy.[2] No specific patent issues tie to vaccine interactions; Cosentyx patents expire around 2032 in major markets.[4]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: ACR Guidelines on Vaccinations in Adults with Rheumatic Diseases
[3]: PubMed: Vaccine Response in IL-17 Inhibitors (2022 Study)
[4]: DrugPatentWatch: Cosentyx Patents